sms pharmaceuticals Limited
Registered & Corporate Office :
8th Floor, Trendset Jayabheri Connect,
Kondapur, Hyderabad - 500 084,
Telangana, India.
Tel : +91 - 40 - 6985 9999
CIN No. : L24239TG1987PLC008066
Email : info@smspharma.com, www.smspharma.com

Date: 31st July, 2026

To

The Manager,	The Manager,
Corporate Filings Department,	Listing Compliance Department,
BSE Limited,	National Stock Exchange of India Ltd.
Phiroze Jeejeebhoy Towers,	Exchange Plaza, Plot no. C/1, G Block,
Dalal Street,	Bandra-Kurla Complex, Bandra (E),
Mumbai- 400 001.	Mumbai - 400 051.
Security Code: 532815	**Symbol: SMSPHARMA**

Dear Sir/Madam,

Subject: Outcome of Board Meeting and Financial Results:

With reference to the cited subject matter, we would like to inform you that the Board of Directors of the Company at its meeting held today i.e., 31st July, 2026, have *inter-alia*, transacted the following item(s) of the Agenda:

Financial Results

1. Approved the standalone and consolidated un-audited Financial Results along with Limited Review Report for the first quarter ended 30th June, 2026.

Annual General Meeting, Book Closure and Record date

1. The 38th Annual General Meeting (AGM) of the company for the Financial Year 2025-26, is scheduled to be held on Wednesday, 23rd September, 2026 through Video Conference or Other Audio-Visual Means as per the Circulars issued by the Ministry of Corporate Affairs and Securities and Exchange Board of India.

2. Approved the Notice of 38th Annual General Meeting (AGM) for the Financial Year 2025-26 and Directors Report along with annexures.

3. The Register of Member and Share Transfer Books of the Company will remain closed from Thursday, 17th September, 2026 to Wednesday, 23rd September, 2026 (both days inclusive) for taking record of the Members of the Company for the AGM.

Registered & Corporate Office :
8th Floor, Trendset Jayabheri Connect,
Kondapur, Hyderabad - 500 084,
Telangana, India.
Tel : +91 - 40 - 6985 9999
CIN No. : L24239TG1987PLC008066
Email : info@smspharma.com, www.smspharma.com

4. The Company has fixed Wednesday 16th September, 2026 as the "Record Date" for the purpose of determining the Members eligible to receive dividend for the financial year 2025-26, if approved at the ensuing AGM and the same will be paid within the stipulated time period.

Further, pursuant to Regulation 33 of the SEBI Listing Regulations, we enclose the following:

Statement of un-audited (Standalone & Consolidated) Financial Results along with the limited review report issued by Statutory Auditors of the Company for the first quarter ended on 30th June, 2026.

Re-appointment

Managing Director of the Company

1. Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have approved the re-appointment of Mr. Ramesh Babu Potluri (DIN:00166381) as a Chairman and Managing Director (Promoter and Executive) of the Company for a term of 5 (Five) consecutive years effective from 01st October, 2026 till 30th September, 2031 (both days inclusive), be liable to retire by rotation.

   The said re-appointment is subject to the approval of the Shareholders of the Company. Mr. Ramesh Babu Potluri (DIN:00166381) is not disqualified from being re-appointed as a Managing Director in terms of the Companies Act 2013 and has given his consent to act as Managing Director.

   Further, in terms of BSE Circular bearing Reference No. LIST/COMP/14/2018-19 and NSE Circular bearing Reference No. NSE/CML/2018/24 dated June 20, 2018, we have received confirmation from Mr. Ramesh Babu Potluri, he is not debarred from accessing capital markets and / or restrained from holding the office of director by virtue of any order of the SEBI or any other such authority.

The details as required in terms of Regulation 30 and Schedule III of the SEBI Listing Regulations, read with SEBI Circular SEBI/HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026 are enclosed as **Annexure I.**

sms pharmaceuticals Limited
Registered & Corporate Office :
8th Floor, Trendset Jayabheri Connect,
Kondapur, Hyderabad - 500 084,
Telangana, India.
Tel : +91 - 40 - 6985 9999
CIN No. : L24239TG1987PLC008066
Email : info@smspharma.com, www.smspharma.com

Giving loan to Subsidiary

Approved to give loan to SMS Peptides Private Limited, Subsidiary Company, up to an aggregate amount not exceeding Rs. 50 Crores, in one or more tranches, subject to approval of shareholders at the ensuing the general meeting, pursuant to Section 185 of the Companies Act, 2013.

The details as required in terms of Regulation 30 and Schedule III of the SEBI Listing Regulations, read with SEBI Circular SEBI/HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026 are enclosed as **Annexure II.**

The meeting commenced at 3.00 p.m. and concluded at 04:20 p.m.

Please take the above intimation on your records.

Thanking you
Yours faithfully

For SMS Pharmaceuticals Limited

THIRUMALESH TUMMA

Digitally signed by THIRUMALESH TUMMA
Date: 2026.07.31 16:54:12 +05'30'

Thirumalesh Tumma
Company Secretary & Compliance Officer

SMS PHARMACEUTICALS LIMITED

(CIN : L24239TG1987PLC008066)

Regd. Office: 8th Floor, Trendset Jayabheri Connect, Kondapur,Serilingampally, Ranga Reddy Dist., Hyderabad-500084.Telangana. India.

Tel: +91-40-6985 9999, Fax :+91-40-2525 9889 ; Email : complianceofficer@smspharma.com

Standalone Statement of Unaudited Financial Results for the Quarter ended 30th June, 2026

(Rs. In Lakhs)

S.No	Particulars	Quarter ended			Year ended
		30/06/2026 (Unaudited)	31/03/2026 (Audited)	30/06/2025 (Unaudited)	31/03/2026 (Audited)
1	**Income**				
	(a) Revenue from Operations	**20,696.49**	23,794.75	19,604.71	88,687.10
	(b) Other Income	**174.44**	257.44	59.31	835.38
	Total Income	**20,870.93**	24,052.19	19,664.02	89,522.48
2	**Expenses**				
	(a) Cost of Materials Consumed	**13,572.13**	12,831.07	14,591.55	51,687.27
	(b) Changes in Inventories	**(2,384.73)**	500.89	(3,568.83)	(2,284.17)
	(c) Manufacturing Expenses	**1,951.54**	2,344.83	1,972.72	9,070.22
	(d) Employee Benefits Expense	**2,330.42**	2,943.49	1,818.49	8,792.34
	(e) Finance Cost	**549.95**	527.67	584.04	2,307.56
	(f) Depreciation and Amortization Expense	**999.08**	1,013.09	975.25	3,991.93
	(g) Other Expenses	**1,038.12**	1,186.59	904.62	4,330.20
	Total Expenses - (a to g)	**18,056.51**	21,347.63	17,277.84	77,895.35
3	**Profit/(loss) Before Exceptional and Extraordinary Items and Tax (1-2)**	**2,814.42**	2,704.56	2,386.18	11,627.13
4	Exceptional items	-	-	-	-
5	**Profit/(loss)Before Extraordinary Items and Tax (3-4)**	**2,814.42**	2,704.56	2,386.18	11,627.13
6	Extraordinary Items	-	-	-	-
7	**Profit/(loss) Before Tax (5-6)**	**2,814.42**	2,704.56	2,386.18	11,627.13
8	Tax Expenses				
	(a) Current Tax relating to Current Period	**610.00**	548.00	500.00	2,598.00
	(b) Current Tax relating to Earlier Period	-	(4.69)	-	(4.69)
	(c) Deferred Tax	**91.16**	69.16	65.43	272.89
	Total Tax Expense	**701.16**	612.47	565.43	2,866.20
9	**Net Profit / (Loss) after Tax (7-8)**	**2,113.26**	2,092.09	1,820.75	8,760.93
10	**Other Comprehensive Income (OCI):**				
	Items that will not be reclassified to profit or Loss:				
	(i) Remeasurement gains/(losses) on defined benefit plans	**(10.00)**	31.32	(12.61)	4.43
	(ii)Income Tax effect on the above	**2.52**	(7.88)	3.17	(1.12)
	Total Other comprehensive Income/(loss),net of tax	**(7.48)**	23.44	(9.44)	3.31
11	**Total Comprehensive Income (9+10)**	**2,105.78**	2,115.53	1,811.31	8,764.24
12	Paid-up equity share capital (Face Value of Re.1/- each)	**936.52**	936.52	886.52	936.52
13	**Other Equity excluding revaluation reserves**				79,542.17
14	Earnings Per Equity Share of (Face Value of Re.1/- each) Basic / Diluted (not annualised)	**2.26**	2.29	2.05	9.58

SMS Pharmaceuticals Ltd. Hyderabad

Notes:

1 The above standalone unaudited financial results have been reviewed by the Audit Committee on July 31, 2026 and approved by the Board of Directors at its meeting held on July 31, 2026. The Statutory Auditors of the Company have carried out a limited review on standalone financial results and have issued an un-modified conclusion in respect of the limited review for the limited review for the quarter ended June 30, 2026.

2 These standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act,2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India (SEBI).

3 The Company is engaged in the manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.

4 The figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures in respect of full financial year ended March 31, 2026 and the unaudited published year to date figures up to third quarter of the financial year ended March 31, 2026, which were subjected to limited review by the statutory auditors. The figures have been regrouped/reclassified as necessary.

For SMS Pharmaceuticals

SMS Pharmaceuticals Ltd. Hyderabad

Place: Hyderabad
Date : Jul 31, 2026

Ramesh Babu Potluri
Chairman and Managing

SURYANARAYANA & SURESH
Chartered Accountants

Flat # C1, Millenium House, # 8-2-601/B,
Road No. 10, Near Zaheer Nagar Cross Road,
Banjara Hills, Hyderabad - 500 034.
040-23386783/35164367
suryanarayanasuresh@gmail.com

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To
The Board of Directors
SMS Pharmaceuticals Limited
Hyderabad.

We have reviewed the accompanying statement of unaudited financial results of SMS Pharmaceuticals Limited ("the Company"), for the quarter ended 30th June 2026. This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

This statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by Independent Auditor of Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the aforesaid Indian Accounting standards and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date: 31.07.2026

For Suryanarayana & Suresh.,
Chartered Accountants
Reg. No.006631S

SURYANARAYANA & SURESH Hyderabad F.R.No: 006631S Chartered Accountants

Muralikrishna Pinamaneni
Partner
M. No. 224319

UDIN: 26224319LHSFKW3571

AIScanner

SMS PHARMACEUTICALS LIMITED

(CIN : L24239TG1987PLC008066)

Regd. Office: 8th Floor, Trendset Jayabheri Connect, Kondapur,Serilingampally, Ranga Reddy Dist., Hyderabad-500084.Telangana. India.

Tel: +91-40-6985 9999, Fax :+91-40-2525 9889 ; Email : complianceofficer@smspharma.com

Consolidated Statement of Unaudited Financial Results for the Quarter Ended 30th June, 2026

(Rs. In Lakhs)

S.No	Particulars	Quarter ended			Year ended
		30/06/2026	31/03/2026	30/06/2025	31/03/2026
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	**Income**				
	(a) Revenue from Operations	**20,696.49**	23,794.75	19,604.71	88,687.10
	(b) Other Income	**174.44**	257.44	59.31	835.38
	Total Income	**20,870.93**	24,052.19	19,664.02	89,522.48
2	**Expenses**				
	(a) Cost of Materials Consumed	**13,664.68**	12,846.05	14,528.60	51,643.79
	(b) Changes in Inventories	**(2,412.93)**	475.58	(3,568.83)	(2,309.48)
	(c) Manufacturing Expenses	**1,951.60**	2,344.83	1,972.72	9,070.22
	(d) Employee Benefits Expense	**2,354.02**	2,946.72	1,818.49	8,795.56
	(e) Finance Cost	**549.95**	527.67	584.07	2,307.56
	(f) Depreciation and Amortization Expense	**999.08**	1,013.09	975.25	3,991.93
	(g) Other Expenses	**1,044.03**	1,191.57	916.82	4,359.14
	Total Expenses - (a to g)	**18,150.43**	21,345.51	17,227.12	77,858.72
3	**Profit/(loss) Before Exceptional and Extraordinary Items and Tax (1-2)**	**2,720.50**	2,706.68	2,436.90	11,663.76
4	Exceptional items	**-**	-	-	-
5	**Profit/(loss)Before Extraordinary Items and Tax (3-4)**	**2,720.50**	2,706.68	2,436.90	11,663.76
6	Extraordinary Items	**-**	-	-	-
7	**Profit/(loss) Before Tax (5-6)**	**2,720.50**	2,706.68	2,436.90	11,663.76
8	Tax Expenses				
	(a) Current Tax relating to Current Period	**610.00**	548.00	500.00	2,598.00
	(b) Current Tax relating to Earlier Period	**-**	(4.69)	-	(4.69)
	(c) Deferred Tax	**90.40**	66.92	65.43	270.66
	Total Tax Expense	**700.40**	610.23	565.43	2,863.97
9	**Net Profit / (Loss) after Tax (7-8)**	**2,020.10**	2,096.45	1,871.47	8,799.79
10	**Share of Profit/(Loss) in Associate,net of tax**	**70.80**	1,174.94	177.58	1,399.12
11	**Net Profit /(loss) after taxes and share of profit/(loss) from associate (9+10)**	**2,090.90**	3,271.39	2,049.05	10,198.91

SMS Pharmaceuticals Ltd. Hyderabad

12	**Other Comprehensive Income (OCI):**				
	Items that will not be reclassified to Profit & Loss				
	(i)Remeasurement Gain / (Loss) of the defined benefit plans	**(10.00)**	31.32	(12.61)	4.43
	(ii)Income Tax effect on the above	**2.52**	(7.88)	3.17	(1.12)
	(iii) Share of Other Comprehensive Income in Associates	**1.30**	6.50	0.87	9.12
	(iv)Share of Income Tax effect on the above in Associates	**(0.32)**	(1.69)	(0.23)	(2.37)
	Total Other comprehensive Income/(loss),net of tax	**(6.50)**	28.25	(8.80)	10.06
13	**Total comprehensive Income (11+12)**	**2,084.40**	3,299.64	2,040.25	10,208.97
14	Profit / (Loss) Attributable to				
	Shareholders of the Company	**2,090.90**	3,271.39	2,049.05	10,198.91
	Non-Controlling Interests	**(0.00)**	0.00	(0.00)	(0.00)
		2,090.90	3,271.39	2,049.05	10,198.91
15	Other Comprehensive Income/(Loss) Attributable to				
	Shareholders of the Company	**(6.50)**	28.25	(8.80)	10.06
	Non-Controlling Interests	**-**	-	-	-
		(6.50)	28.25	(8.80)	10.06
16	Total comprehensive income attributable to:				
	Shareholders of the Company	**2,084.40**	3,299.64	2,040.25	10,208.97
	Non-Controlling Interests	**(0.00)**	0.00	(0.00)	(0.00)
		2,084.40	3,299.64	2,040.25	10,208.97
17	Paid-up equity share capital (Face Value of Re.1/- each)	**936.52**	936.52	886.52	936.52
18	Other Equity excluding revaluation reserve				77,644.36
19	Earnings Per Equity Share of (Face Value of Re.1/- each) Basic / Diluted (not annualised)	**2.23**	3.58	2.31	11.15

SMS Pharmaceuticals Ltd. Hyderabad

Notes:

1. The above Consolidated unaudited financial results have been reviewed by the Audit Committee on July 31, 2026 and approved by the Board of Directors at its meeting held on July 31, 2026. The Statutory Auditors of the Company have carried out a limited review on consolidated financial results and have issued an un-modified conclusion in respect of the limited review for the limited review for the quarter ended June 30, 2026.

2. These consolidation financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act,2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India (SEBI).

3. VKT Pharma Private Limited is considered as an Associate Company for the consolidation in which the Company holds 34.83% as on June 30, 2026 in their equity. Accordingly, the results include appropriate share of the results of said Associate.

4. The Company has joint venture namely "Chemo SMS Enterprises SL" in which there were no financial operations during the reporting period, hence, this entity is not considered for consolidation.

5. SMS coLab Private Limited, which is a wholly owned subsidiary company and SMS Peptides Private Limited, which is a subsidiary company, have incurred expenditure and assets, which have been appropriately consolidated in the financial statements for the reporting period in compliance with the applicable Indian Accounting Standards (Ind AS).

6. Consolidated Financial Statements have been prepared by applying Accounting Standard "Ind AS 28 "Investments in Associates and Joint Ventures" as applicable under the Companies Act,2013 and applicable rules there under.

7. The Group is engaged in the manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.

8. The figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures in respect of full financial year ended March 31, 2026 and the unaudited published year to date figures up to third quarter of the financial year ended March 31, 2026, which were subjected to limited review by the statutory auditors. The figures have been regrouped/reclassified as necessary.

For SMS Pharmaceuticals

SMS Pharmaceuticals Ltd. Hyderabad

Ramesh Babu Potluri
Chairman and Managing

Place: Hyderabad
Date : Jul 31, 2026

SURYANARAYANA & SURESH
Chartered Accountants

Flat # C1, Millenium House, # 8-2-601/B,
Road No. 10, Near Zaheer Nagar Cross Road,
Banjara Hills, Hyderabad - 500 034.
040-23386783/35164367
suryanarayanasuresh@gmail.com

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of SMS Pharmaceuticals Limited,

1. We have reviewed the accompanying statement of unaudited consolidated financial results of SMS PHARMACEUTICALS LIMITED (the "Holding Company") and its subsidiary, Associate and Joint Venture (the Holding Company and its subsidiary, Associate & Joint Venture together referred to as 'the Group') for the quarter ended June 30, 2026 (the "statement"), attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.

3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial information performed by the Independent Auditor of the Entity,* issued by Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review of interim financial information consists of making inquiries, primarily of personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit.

   Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

SURYANARAYANA & SURESH
Hyderabad
F.R.No: 006631S
Chartered Accountants

4. The Statement includes the share of profit/(loss) result of the following Subsidiary/Associate /Joint Venture:

   a. SMS Peptides Private Limited (Subsidiary Company)
   b. VKT Pharma Private Limited (Associate Company)
   c. SMS CoLab Private Limited (Wholly owned Subsidiary Company)
   d. Chemo SMS Enterprises SL (Joint Venture)

5. Based on our review conducted above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard (Ind AS) specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matter

6. The consolidated financial results includes the unaudited financial statements/ financial results of Subsidiary namely SMS Peptides Private Limited which have been reviewed by us whose financial statements / Unaudited financial results reflect total revenue of Rs. Nil lakhs, total net Loss after tax of Rs.2.00 lakhs and total comprehensive loss is Rs.2.00 lakhs for the quarter ended June 30, 2026.

7. The consolidated financial results includes the unaudited financial statements/ financial results of associate namely VKT Pharma Private Limited which have been reviewed by their auditor whose financial statements / Unaudited financial results reflect total revenue of Rs. 4,692.61 lakhs, total net profit after tax of Rs.203.31 lakhs and total comprehensive income of Rs.206.11 lakhs for the quarter ended June 30, 2026.

8. The consolidated financial results includes the unaudited financial statements/ financial results of Subsidiary namely SMS CoLab Private Limited which have been reviewed by us whose financial statements / Unaudited financial results reflect total revenue of Rs. Nil lakhs, total net Loss after tax of Rs.0.15 lakhs and total comprehensive income of Rs.0.15 lakhs for the quarter ended June 30, 2026.

SURYANARAYANA & SURESH
Hyderabad
F.R.No: 006631S
Chartered Accountants

9. The consolidated financial results also include the unaudited financial results of joint venture namely M/s Chemo SMS Enterprises SL in which there is no operations during the quarter ended June 30, 2026. Hence, there is no significant effect on the financial statements and not material to the group.

Our conclusion on the Statement is not modified in respect of the above matters.

Place: Hyderabad
Date: 31.07.2026

UDIN: 26224319DWOYLK5341

For Suryanarayana & Suresh.,
Chartered Accountants
Reg. No.006631S

Muralikrishna Pinamaneni
Partner
M. No. 224319

SURYANARAYANA & SURESH
Hyderabad
F.R.No: 006631S
Chartered Accountants

sms pharmaceuticals Limited
Registered & Corporate Office :
8th Floor, Trendset Jayabheri Connect,
Kondapur, Hyderabad - 500 084,
Telangana, India.
Tel : +91 - 40 - 6985 9999
CIN No. : L24239TG1987PLC008066
Email : info@smspharma.com, www.smspharma.com

Annexure -I

Sr. No.	Particulars	Details
1.	Reason for change viz. ~~appointment~~, re-appointment, ~~resignation, removal, death or otherwise~~	Mr. Ramesh babu Potluri has been re-appointed as Chairman and Managing Director of the company.
2.	Date of ~~appointment~~/re-appointment/~~cessation~~ (as applicable) & Term of appointment/re-appointment	Re-appointed for further period of 5 (five) years commencing from 01st October, 2026 to 30th September, 2031, subject to approval of the shareholders at the ensuing general meeting.
3.	Brief Profile (in case of appointment):	Mr. Ramesh Babu Potluri is a Post-Graduate Technocrat with over four decades of distinguished experience in the pharmaceutical industry, particularly in research & development, process innovation, manufacturing, and business leadership. In 1990, he acquired SMS Pharmaceuticals Limited, which was then a sick Company. Under his leadership, the Company successfully restructured its product portfolio, achieved profitability in the very first year of operations, introduced several Active Pharmaceutical Ingredients (APIs), and emerged as one of the leading manufacturers of Ranitidine Hydrochloride. Apart from his corporate leadership, he has made significant contributions to the pharmaceutical industry by serving on the Boards of various industry organizations, including Chemexcil. He has also served as an Advisor to the Government of Andhra Pradesh on matters relating to the pharmaceutical sector.
4.	Disclosure of relationships between Directors (in case of appointment of a Director).	Mr. Ramesh Babu Potluri, Chairman and Managing Director of the Company and Mr. Vamsi Krishna Potluri, executive Director and Mr. Trilok Potluri Non-Executive Director are his sons.

sms®
pharmaceuticals Limited
Registered & Corporate Office :
8th Floor, Trendset Jayabheri Connect,
Kondapur, Hyderabad - 500 084,
Telangana, India.
Tel : +91 - 40 - 6985 9999
CIN No. : L24239TG1987PLC008066
Email : info@smspharma.com, www.smspharma.com

Annexure -II

Sr. No.	Particulars	Details
1.	name(s) of parties with whom the agreement is entered	M/s. SMS Peptides Private Limited, Subsidiary Company, (CIN: U21000TS2024PTC190643)
2.	purpose of entering into the agreement	To provide loan to M/s. SMS Peptides Private Limited for business purpose.
3.	size of agreement	Proposed to give loan up to an aggregate amount not exceeding Rs. 50 Crores, in one or more trenches.
4.	shareholding, if any, in the entity with whom the agreement is executed	The Company is holding 99.99% stake in the Subsidiary Company as on date.
5.	significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc	No such special rights
6.	whether, the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship	Yes, M/s. SMS peptides Private Limited is the Subsidiary of M/s. SMS pharmaceuticals Limited & having common Directors
7.	whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	Yes, the transaction is at arm's length basis.
8.	in case of issuance of shares to the parties, details of issue price, class of shares issued	Not Applicable
9.	in case of loan agreements, details of lender/borrower, nature of the loan, total amount of loan granted/taken, total amount outstanding, date of execution of the loan agreement/sanction letter, details of the security provided to the lenders /	Lender: SMS Pharmaceuticals Limited Borrower: M/s. SMS Peptides Private Limited Nature of loan: Unsecured loan Amount of loan: Up to an aggregate amount not exceeding Rs. 50 Crores (Rupees Fifty Crore Only) Date of execution of Loan Agreement: The

Registered & Corporate Office :
8th Floor, Trendset Jayabheri Connect,
Kondapur, Hyderabad - 500 084,
Telangana, India.
Tel : +91 - 40 - 6985 9999
CIN No. : L24239TG1987PLC008066
Email : info@smspharma.com, www.smspharma.com

	by the borrowers for such loan or in case outstanding loans lent to a party or borrowed from a party become material on a cumulative basis	Company will enter into a loan agreement subsequent to the approval of the shareholders. Amount of loan outstanding as on date of disclosure – Nil
10.	any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc	NIL
11.	In case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s): i. name of parties to the agreement; ii. nature of the agreement; iii. date of execution of the agreement; iv. details of amendment and impact thereof or reasons of termination and impact thereof	Not Applicable